- Report
- April 2025
- 175 Pages
Global
From €4098EUR$4,490USD£3,494GBP
- Report
- May 2024
- 131 Pages
Global
From €5931EUR$6,499USD£5,057GBP
- Report
- May 2024
- 138 Pages
Global
From €5931EUR$6,499USD£5,057GBP
- Report
- October 2024
- 318 Pages
Global
From €7255EUR$7,950USD£6,186GBP
- Report
- March 2024
- 30 Pages
Global
From €2966EUR$3,250USD£2,529GBP
- Report
- February 2024
- 115 Pages
Global
From €4335EUR$4,750USD£3,696GBP
- Report
- June 2018
- 16 Pages
Global
From €9126EUR$10,000USD£7,782GBP
- Report
- April 2023
- 77 Pages
Global
From €3500EUR$4,108USD£3,089GBP
- Report
- November 2021
- 844 Pages
Global
From €4563EUR$5,000USD£3,891GBP
Rasagiline is a drug used to treat symptoms of Parkinson's disease. It is a monoamine oxidase inhibitor (MAOI) and is used to increase the levels of dopamine in the brain. It is also used to treat depression and other psychiatric disorders. It is available in both oral and transdermal forms.
Rasagiline is one of the most commonly prescribed drugs for the treatment of Parkinson's disease. It is also used to treat other neurological disorders such as restless leg syndrome and depression. It is generally well tolerated and has few side effects.
The market for rasagiline is highly competitive, with many companies offering different formulations of the drug. Some of the major players in the market include Teva Pharmaceuticals, Mylan, Sun Pharmaceuticals, and Novartis. Other companies such as Merck, Pfizer, and GlaxoSmithKline also offer rasagiline in various forms. Show Less Read more
